[Retracted] A Data-Driven Medical Decision Framework for Associating Adverse Drug Events with Drug-Drug Interaction Mechanisms

Table 3

Selected potentially significant ADEs and corresponding counts of associated DDI mechanisms.

No. of associations	ADEs (HPO)
6 mechanisms	Abnormal inflammatory response
5 mechanisms	Neurological speech impairment
	Dysphonia
	Abnormality of body weight
	Pancreatitis
	Abnormality of leukocytes
	Abnormality of bone marrow cell morphology
	Abnormality of erythrocytes
	Abnormality of cells of the erythroid lineage
	Pancytopenia
	Abnormality of multiple cell lineages in the bone marrow
	Thrombocytopenia
4 mechanisms	Abnormality of higher mental function
	Growth abnormality
	Decreased body weight
3 mechanisms	Abnormal emotion/affect behaviour
	Restlessness
	Thrombophlebitis
	Venous thrombosis
	Diabetes mellitus
	Increased body weight
	Seizure
2 mechanisms	Sleep disturbance
	Ketosis
	Abnormal platelet count
	Rheumatoid arthritis
	Hematological neoplasm
1 mechanism	Abnormality of carbohydrate metabolism/homeostasis
	Abnormal glucose homeostasis
	Hypoglycemia
	Abnormal thrombosis
	Diabetic ketoacidosis
	Excessive daytime somnolence
	Reduced consciousness/confusion
	Psychosis
	Abnormality of the urinary system physiology
	Leukopenia
	Acute kidney injury
	Renal insufficiency
	Abnormality of neutrophils
	Abnormality of prenatal development or birth
	Hepatomegaly
	Skin rash
	Multiple myeloma
	Metrorrhagia
	Menstrual irregularities
	Puberty and gonadal disorders
	Abnormality of female internal genitalia
	Abnormality of the cardiovascular system
	Arteriosclerosis
	Abnormality of the systemic arterial tree
	Lymphadenopathy
	Abnormality of the lymph nodes